HanchorBio is a company headquartered in Taiwan. Brouky records 1 investor associated with the company.
HanchorBio is an immune-oncology company that engineers Fc-Based Designer Biologics (FBDB™) to create ligand traps that block multi-ligand interactions involved in adaptive and innate immune activation. Its lead candidate HCB101 is a ligand trap targeting the SIPRα-CD47 signaling pathway and is in US Phase 1 clinical studies for advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.